FDA Calls Out “Egregious” Novartis Petition; Firm Asks Agency To Be Nicer
Executive Summary
After the agency reproaches Novartis for what it called a tardy petition seeking to block generic versions of Reclast, the firm offers more information, not in an effort to get FDA to change its mind, but just to change its tone.
You may also be interested in...
Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say
FDA posts non-compliance letters and responses from three sponsors that failed to meet deadlines for submitting reports for trials of four drugs in children; more than 70 firms have had their deadlines extended.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.